Home > Press > Nanomaterials, nanomedicine lab dedicated at UNM, with help from Sandia
Abstract:
It wasn't exactly the grand opening of a research megacenter, but the dedication Aug. 23 of the third floor of the University of New Mexico's Centennial Engineering Center for a lab combining nanotechnology and nanomedicine offered a start-up charm of its own. Maybe Los Alamos National Laboratory in its early days was something like this.
Clustered in a hallway on a floor of green tiles, with lights, pipes and vents visible overhead, about 50 informally dressed students and sports-jacketed faculty looked on as Sandia fellow and UNM professor Jeff Brinker, UNM School of Engineering dean Catalin Roman, UNM Cancer Center director Cheryl Willman and other administrators explained to three New Mexico state representatives, sitting in an adjacent bubble-like room, why the $2 million the state had contributed to the new facility was a good idea.
Brinker, who spearheaded the drive to create the 5,000-square-foot lab, spoke first: "I used to be content in making materials, but as my wife used to say: ‘Have you saved anyone's life today? What have you really done?'"
Prominently displayed on the wall was work led by Brinker, published in the most highly respected science journals. Most prominent was a paper detailing the creation by the Brinker group of pore-riddled nanospheres they termed ‘protocells,' capable of encapsulating and delivering unusually large amounts of cancer-destroying chemicals directly to a cancerous cell.
The protocell work, said Willman, has led to numerous calls from drug companies near Boston and in San Diego, "but we prefer to start a company in New Mexico to bring these achievement to market."
She pointed out to the legislators that, because of the Cancer Center's joint work with Brinker and Sandia, UNM is a member with three other institutions — Harvard University, the California Institute of Technology and the Massachusetts Institute of Technology — of the National Cancer Institute's Nanotechnology Alliance, which has brought millions of federal dollars into New Mexico. The nanobio-nanomedicine lab should help produce more medical breakthroughs from New Mexico, she said.
The lab contains areas to continue work on cancers and low-level pathogens, and to create and analyze new nanomaterials. "For commercial purposes, we have to demonstrate good manufacturing practices that show dosage control, purity, reproducibility and other factors in our protocells," said UNM post-doctoral student Carlee Ashley, who led development of the nanoscale medicine transporters as part of her doctoral project under Brinker's tutelage. "And we have to demonstrate removal of toxins that can contaminate our work, before applying to the [Food and Drug Administration] for human trials."
####
About Sandia National Laboratories
Sandia National Laboratories is a multiprogram laboratory operated and managed by Sandia Corporation, a wholly owned subsidiary of Lockheed Martin Corporation, for the U.S. Department of Energy’s National Nuclear Security Administration. With main facilities in Albuquerque, N.M., and Livermore, Calif., Sandia has major R&D responsibilities in national security, energy and environmental technologies, and economic competitiveness.
For more information, please click here
Contacts:
Neal Singer
( 505 ) 845-7078
Copyright © Sandia National Laboratories
If you have a comment, please Contact us.Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Related News Press |
News and information
Beyond wires: Bubble technology powers next-generation electronics:New laser-based bubble printing technique creates ultra-flexible liquid metal circuits November 8th, 2024
Nanoparticle bursts over the Amazon rainforest: Rainfall induces bursts of natural nanoparticles that can form clouds and further precipitation over the Amazon rainforest November 8th, 2024
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Laboratories
A battery’s hopping ions remember where they’ve been: Seen in atomic detail, the seemingly smooth flow of ions through a battery’s electrolyte is surprisingly complicated February 16th, 2024
NRL discovers two-dimensional waveguides February 16th, 2024
Openings/New facilities/Groundbreaking/Expansion
OCSiAl expands its graphene nanotube production capacities to Europe June 17th, 2022
GLOBALFOUNDRIES Moves Corporate Headquarters to its Most Advanced Semiconductor Manufacturing Facility in New York April 27th, 2021
Oxford Instruments Plasma Technology relocates to advanced manufacturing facility: Move driven by exceptional business growth February 12th, 2021
Govt.-Legislation/Regulation/Funding/Policy
New discovery aims to improve the design of microelectronic devices September 13th, 2024
Physicists unlock the secret of elusive quantum negative entanglement entropy using simple classical hardware August 16th, 2024
Single atoms show their true color July 5th, 2024
Nanomedicine
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Unveiling the power of hot carriers in plasmonic nanostructures August 16th, 2024
Materials/Metamaterials/Magnetoresistance
Nanoscale CL thermometry with lanthanide-doped heavy-metal oxide in TEM March 8th, 2024
Focused ion beam technology: A single tool for a wide range of applications January 12th, 2024
Announcements
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||